🇺🇸 FDA
Patent

US 12345709

CLAUDIN18 antibodies and methods of treating cancer

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 12345709 (CLAUDIN18 antibodies and methods of treating cancer) held by The Regents of the University of California expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K47/68031, A61K47/6849